These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21620441)

  • 1. Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis from the AURICULA registry in Sweden.
    Jönsson KM; Wieloch M; Sterner G; Nyman U; Elmståhl S; Engström G; Svensson PJ
    Thromb Res; 2011 Oct; 128(4):341-5. PubMed ID: 21620441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics).
    Poli D; Antonucci E; Zanazzi M; Grifoni E; Testa S; Ageno W; Palareti G
    Thromb Haemost; 2012 Jun; 107(6):1100-6. PubMed ID: 22535516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
    Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L
    Circulation; 2014 Mar; 129(9):961-70. PubMed ID: 24323795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.
    Wieloch M; Själander A; Frykman V; Rosenqvist M; Eriksson N; Svensson PJ
    Eur Heart J; 2011 Sep; 32(18):2282-9. PubMed ID: 21616951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.
    O'Meara E; Khairy P; Blanchet MC; de Denus S; Pedersen OD; Levesque S; Talajic M; Ducharme A; White M; Racine N; Rouleau JL; Tardif JC; Roy D;
    Circ Heart Fail; 2012 Sep; 5(5):586-93. PubMed ID: 22798522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study.
    White SL; Polkinghorne KR; Atkins RC; Chadban SJ
    Am J Kidney Dis; 2010 Apr; 55(4):660-70. PubMed ID: 20138414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of edaravone on the estimated glomerular filtration rate in patients with acute ischemic stroke and chronic kidney disease.
    Tsukamoto Y; Takizawa S; Takahashi W; Mase H; Miyachi H; Miyata T; Takagi S
    J Stroke Cerebrovasc Dis; 2011; 20(2):111-6. PubMed ID: 20580255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The practical implications of using standardized estimation equations in calculating the prevalence of chronic kidney disease.
    Quinn MP; Rainey A; Cairns KJ; Marshall AH; Savage G; Kee F; Peter Maxwell A; Reaney E; Fogarty DG
    Nephrol Dial Transplant; 2008 Feb; 23(2):542-8. PubMed ID: 17890743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.
    Carrero JJ; Evans M; Szummer K; Spaak J; Lindhagen L; Edfors R; Stenvinkel P; Jacobson SH; Jernberg T
    JAMA; 2014 Mar; 311(9):919-28. PubMed ID: 24595776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower-dose warfarin delays renal progression and prolongs patient survival in patients with stage 3 - 5 chronic kidney disease and nonvalvular atrial fibrillation: a 12-year follow-up study.
    Chiu PF; Huang CH; Liou HH; Wu CL; Chang C; Chang CC; Chang HR
    Int J Clin Pharmacol Ther; 2014 Jun; 52(6):504-8. PubMed ID: 24755133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction.
    Szummer K; Gasparini A; Eliasson S; Ärnlöv J; Qureshi AR; Bárány P; Evans M; Friberg L; Carrero JJ
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28249846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of chronic kidney disease based on estimated glomerular filtration rate and proteinuria in Icelandic adults.
    Viktorsdottir O; Palsson R; Andresdottir MB; Aspelund T; Gudnason V; Indridason OS
    Nephrol Dial Transplant; 2005 Sep; 20(9):1799-807. PubMed ID: 15928100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry).
    Kowey PR; Reiffel JA; Myerburg R; Naccarelli GV; Packer DL; Pratt CM; Reiter MJ; Waldo AL;
    Am J Cardiol; 2010 Apr; 105(8):1130-4. PubMed ID: 20381665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of atrial fibrillation in a geographically well-defined population in northern Sweden: implications for anticoagulation prophylaxis.
    Andersson P; Löndahl M; Abdon NJ; Terent A
    J Intern Med; 2012 Aug; 272(2):170-6. PubMed ID: 22250988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
    Lip GY; Frison L; Halperin JL; Lane DA
    J Am Coll Cardiol; 2011 Jan; 57(2):173-80. PubMed ID: 21111555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding).
    Roldán V; Marín F; Fernández H; Manzano-Fernández S; Gallego P; Valdés M; Vicente V; Lip GY
    Am J Cardiol; 2013 Apr; 111(8):1159-64. PubMed ID: 23337836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence and quality of anticoagulant treatment of chronic atrial fibrillation in primary health care in Sweden: a retrospective study on electronic patient records.
    Nilsson GH; Björholt I
    BMC Clin Pharmacol; 2004 Feb; 4():1. PubMed ID: 15028124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of decreased glomerular filtration rate in patients seeking non-nephrological medical care--an evaluation using IDMS-traceable creatinine based MDRD as well as Mayo Clinic quadratic equation estimates.
    Risch L; Saely CH; Neyer U; Hoefle G; Gouya G; Zerlauth M; Risch GM; Risch M; Drexel H
    Clin Chim Acta; 2007 Mar; 378(1-2):71-7. PubMed ID: 17157286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.